-
2023-509247-27-00
5
Neonatal respiratory distress.
Pain and discomfort
-
2024-510602-90-00
5
Patients presenting with acute myocarditis proven by cardiac magnetic
-
2024-513724-42-00
10
Medulloblastoma
-
2024-513889-19-00
5
Multiple Myeloma
-
2024-515362-13-00
10
Philadelphia-negative myeloproliferative neoplasms are frequent and ch
-
2024-516167-86-00
5
Patients referred for an isolated or a combined surgical correction of
-
2024-518146-25-00
5
patients with atrial fibrillation and preserved left ventricular eject
-
2023-507470-40-00
10
2024-08-27
Vitiligo
-
2023-508099-12-00
5
2024-06-20
Dermatitis atopic
-
2023-505486-92-00
4
2024-02-09
Small bowel adenocarcinoma
-
2023-506548-18-00
10
2022-11-10
Dermatitis atopic
-
2024-516807-17-00
4
2019-01-02
Relapsing/Refractory ALK+ Anaplastic Large cell Lymphoma
-
2025-524297-42-00
5
2026-06-12
CLTI defined as Rutherford category 4 or 5
-
2024-513410-35-00
5
2026-05-12
aneurysmal subarachnoid hemorrhage
-
2023-505046-26-00
5
2026-05-07
Colon carcinoma
-
2023-504847-15-00
5
2025-07-21
vaso-occlusive crisis due to sickle cell disease
-
2024-515787-31-00
5
2025-07-18
Patient with early triple-negative breast cancer (TNBC) achieving path
-
2024-516418-39-00
5
2025-07-09
Multiple Myeloma
-
2023-508132-65-00
4
2025-06-30
NEUROENDOCRINE CELLS HYPERPLASIA OF INFANCY
-
2023-504511-32-00
5
2025-05-24
Any patients ≥18 years old, eligible for transfemoral TAVI with covera
-
2023-509787-15-00
5
2025-02-17
Patients with localised prostate cancer and high-risk features of rela
-
2023-508798-94-00
5
2025-02-11
Heart failure
-
2023-508148-23-01
5
2024-12-02
chronically occluded coronary artery
-
2023-508208-40-00
10
2024-11-21
All adult patients with successful transfemoral trans-aortic valve imp